

7 October 2026

AGM & Director Nominations

In accordance with ASX Listing Rule 3.13.1 BLS Pharmaceuticals Limited (ASX:**BLS**) advises that it will hold its next Annual General Meeting ('**AGM**') on 24 November 2026 at 4:00pm AEDT.

Further information in relation to the meeting will be released in the coming weeks.

The closing date for the receipt of nominations from persons wishing to be considered for election as a director of the Company is 19 October 2026. Any nominations must be received in writing and delivered to guy@blspharma.com or to the Company's registered office at Suite 506 Level 50 Clarence Street Sydney NSW 2000 by no later than 5:00pm (AEDT) on 19 October 2026.

This notice has been approved for release by the Company Secretary.

Guy Robertson

Company Secretary BLS Pharmaceuticals Limited



About BLS Pharmaceuticals Limited

BLS Pharmaceuticals Limited (ASX:BLS) is an Australian pharmaceutical company focused on the manufacture, development and commercialisation of regulated therapeutic products and active pharmaceutical ingredients. Through its wholly owned subsidiary, Breathe Life Sciences, the Company operates a GMP-licensed manufacturing, import, export and distribution platform spanning medicinal cannabis, psychedelic medicines and other controlled pharmaceutical products.

BLS maintains operations across Australia, Europe, the United Kingdom and Japan, supplying pharmaceutical products and manufacturing services to regulated international markets through a growing network of commercial partners.

About Breathe Life Sciences (BLS)

Breathe Life Sciences (BLS) is a wholly owned subsidiary of BLS Pharmaceuticals Limited and a GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances, including medicinal cannabis, psilocybin and MDMA.

Established in 2018, BLS has developed an international pharmaceutical manufacturing and distribution platform with operations across Australia, Japan, Scotland (UK) and Europe. The business specialises in final dose-form manufacturing, pharmaceutical distribution, contract manufacturing, international supply and the development of regulated therapeutic products.

BLS sources pharmaceutical raw materials and active pharmaceutical ingredients from a global supplier network and manufactures products for both its own brands and third-party customers. The Company owns the Dr Watson® brand portfolio across multiple international markets and supplies pharmaceutical products, active pharmaceutical ingredients and manufacturing services to customers globally.

In addition to its medicinal cannabis operations, BLS holds licences and capabilities supporting the manufacture, import, export and distribution of a range of regulated pharmaceutical products, positioning the business to participate in emerging therapeutic markets, including psychedelic medicines.

Corporate: [blspharma.com](https://www.blspharma.com)

Australia: [bls.com.au](https://www.bls.com.au)

International: [breathelifesciences.com](https://www.breathelifesciences.com)